In a historic move, the U.S. and Australia have signed a $53 billion minerals framework, investing over $3 billion in critical projects. This partnership aims to enhance supply-chain security and bolster defense cooperation.
In a shocking revelation, Marco Rubio allegedly made a secret deal with El Salvador’s president to hand over U.S. informants, risking law enforcement lives to facilitate Trump's mass deportation of Venezuelans. This controversial agreement threatens ongoing investigations into MS-13 gang ties.
After failing to secure long-range Tomahawk missiles during his US visit, Ukraine's President Zelenskyy warns allies against appeasing Russia. As winter nears, attacks on Ukraine's infrastructure escalate, leaving civilians in peril.
A major shareholder in Core Scientific is set to reject the proposed $5 billion acquisition by rival CoreWeave, raising doubts about one of 2023's largest data center mergers. Trip Miller of Gullane Capital argues the deal undervalues Core Scientific, while CoreWeave defends it as a strategic move. The upcoming vote on October 30 could reshape the future of both companies amidst growing investor concerns.
In a whirlwind week, Trump celebrates a Middle East ceasefire while shifting focus to Russia and Ukraine. Can his newfound momentum translate into peace with these global adversaries?
In a groundbreaking move, Indiana University has secured football coach Curt Cignetti with a stunning $93 million contract, making him the third-highest paid coach in the nation. Discover how this decision signifies a new era for Hoosier football!
Missed Amazon's Prime Day? Don't worry! Exceptional discounts on AirPods 4, Lego Grogu, and smart devices are still available. Discover the best deals and grab your favorites now!
Apple is reportedly finalizing a deal to acquire the talent and technology of computer vision startup Prompt AI. The deal is set to impact employees and users of Prompt's Seemour app, which will be discontinued.
In a major move against high prescription costs, AstraZeneca has agreed to sell its drugs at a discount through Medicaid, marking a significant win for the Trump administration's healthcare initiative.
As fears mount over a potential AI bubble burst, industry leaders express concerns about overvaluation and financial engineering in Silicon Valley. Experts warn that the repercussions could extend beyond tech.
